Maribavir: Adis Evaluation

Key Points

- A CMV enzyme pUL97 kinase inhibitor is being developed by Takeda Pharmaceuticals for the treatment of CMV infections
- Received its first approval on 23 Nov 2021 in the USA
- Approved for use in adults and paediatric patients (≥ 12 years of age and weighing ≥ 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet

Summary

Maribavir (LIVTENCITY™), a cytomegalovirus (CMV) enzyme pUL97 kinase inhibitor, is being developed by Takeda Pharmaceuticals for the treatment of CMV infections.

Maribavir was recently approved in the USA for the treatment of post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet in adults and paediatric (≥ 12 years of age and weighing ≥ 35 kg) patients.

This article summarizes the milestones in the development of maribavir leading to this first approval for CMV infections.

This summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © Springer Nature Switzerland AG 2022.

Kang, C. Drugs. 2022. https://doi.org/10.1007/s40265-022-01677-4